A Philadelphia founder has been using artificial intelligence for life sciences materials since 2015, long before the mainstream hype for the tech.

The purpose of the incorporation of this wholly owned subsidiary is to expand the biopharma products business in Europe.

GIC Re on Monday posted a 17% decline in net profit to ₹2,183 crore for the fourth quarter ended March 2025. The state-owned ...

Acadia Pharmaceuticals ACAD shares surged 26.5% on Friday after the company announced that the U.S. District Court in ...

Aurobindo Pharma ... to prior therapy, the company said. This is the 181st ANDA approval, including nine tentative approvals received, out of Eugia Pharma Specialities Group (EPSG) facilities ...

Aurobindo Pharma ... pharma companies into the GLP-1 drug market is expected to bolster long-term growth prospects, although revenue realisation from these efforts may take time. The brokerage's ...

Aurobindo Pharma announced on Saturday that its US-based business has signed a licensing arrangement with a global pharmaceutical company for the development of respiratory treatments. Aurobindo ...

The UBS report also considered Aurobindo Pharma's financial projections, stating that the company's mid-single-digit earnings growth profile for its base business, excluding gRevlimid, and a 12% ...

In an August discussion, Aurobindo Pharma’s management stated that the company’s business team is confident of Eugia’s revenues of $600 million in Fiscal Year 2025, and that the remediation ...

The company is accelerating its growth trajectory to capitalize on the market opportunities. (Image Credits: Pixabay) Aurobindo Pharma, a key player in the pharmaceutical industry, is focused on ...

GlobalData’s report on Aurobindo Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here. According to GlobalData’s company profile on Aurobindo Pharma, ...